|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 全球动脉粥样硬化血栓形成门诊患者中心血管危险因素的患病率、认知和治疗显示文摘Context: Atherothrombosis is the leading cause of cardiovascular morbidity and mortality around the globe. To date, no single international database has characterized the atherosclerosis risk factor profile or treatment intensity of individuals with atherothrombosis. Objective: To determine whether atherosclerosis risk factor prevalence and treatment would demonstrate comparable patterns in many countries around the world. Design, Setting, and Participants: The Reduction of Atherothrombosis for Continued Health(REACH) Registry collected data on atherosclerosis risk factors and treatment. A total of 67 888 patients aged 45 years or older from 5473 physician practices in 44 countries had either established arterial disease(coronary artery disease[CAD], n=40 258; cerebrovascular disease, n=18843; peripheral arterial disease, n=8273) or 3 or more risk factors for atherothrombosis(n=12 389) between 2003 and 2004. Main Outcome Measures: Baseline prevalence of atherosclerosis risk factors, medication use, and degree of risk factor control. Results: Atherothrombotic patients throughout the world had similar risk factor profiles: a high proportion with hypertension(81.8% ), hypercholesterolemia(72.4% ), and diabetes(44.3% ). The prevalence of overweight(39.8% ), obesity(26.6% ), and morbid obesity(3.6% ) were similar in most geographic locales, but was highest in North America(overweight: 37.1% , obese: 36.5% , and morbidly obese: 5.8% ; P< .001 vs other regions). Patients were generally undertreated with statins(69.4% overall; range: 56.4% for cerebrovascular disease to 76.2% for CAD), antiplatelet agents(78.6% overall; range: 53.9% for ≥ 3 risk factors to 85.6% for CAD), and other evidence-based risk reduction therapies. Current tobacco use in patients with established vascular disease was substantial(14.4% ). Undertreated hypertension(50.0% with elevated blood pressure at baseline), undiagnosed hyperglycemia(4.9% ), and impaired fasting glucose(36.5% in those not known to be diabetic) were common. Among those with symptomatic atherothrombosis, 15.9% had symptomatic polyvascular disease. Conclusion: This large, international, contemporary database shows that classic cardiovascular risk factors are consistent and common but are largely undertreated and undercontrolled in many regions of the world. | Bhatt D.L Gabriel Steg P Magnus Ohman E. 黄浙勇 | 2006 | 世界核心医学期刊文摘(心脏病学分册)2006，2，5： | 5 |
| 2 | 心率作为冠心病与左室收缩障碍患者的预后危险因素(BEAUTIFUL):一项随机、对照试验的一个亚组分析显示文摘背景BEAUTIFUL研究对降心率药物伊伐布雷定的发病率与病死率收益进行了评估。BEAUTIFUL试验中的安慰剂组是由稳定型冠心病与左室收缩功能障碍的大型患者队列组成。我们对该安慰剂组进行了亚组分析,旨在检验这样一种假设,即基线静息心率升高是心血管疾病发病与死亡的标志。
方法采用Cox比例风险模型,对心率≥70次/min患者(2693例)以及〈70次/min患者(2745例)进行对比,分析基线静息心率与心血管结局之间的关系。将心率作为一个连续变量,并采用更为精细的心率分类进行其他分析。
结果在对基线特征进行校正后,心率≥70次/min患者的心血管疾病死亡(34%,P=0.0041)、心力衰竭入院(53%,P=0.0001)、心肌梗死入院(46%,P=0.0066)及冠状动脉血运重建(38%,P=0.037)风险升高。心率每升高5次/min,患者的心血管疾病死亡(8%,P=0.0005)、心力衰竭入院(16%.P〈0.0001)、心肌梗死入院(7%,P=0.052)及冠状动脉血运重建(8%,P=0.034)风险亦升高。对心率精细分组的分析表明,心率〉70次/min患者的病死率与心力衰竭发生率持续升高,但这种相关性在冠状动脉结局方面并不显著。对于心力衰竭结局而言,静息心率对早期事件的预测价值较晚期事件的预测价值更强。
结论在冠心病和左室收缩功能障碍的患者中,心率升高(≥70次/min)意味着心血管疾病结局风险升高,同时对心力衰竭相关性结局与冠状动脉事件相关性结局有着不同的影响。 | Kim Fox Ian Ford P Gabriel Steg Michal Tendera Michele Robertson Roberto Ferrari 罗亮(译) | 2008 | 世界临床医学2008，2，6： | 5 |
| 3 | Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions显示文摘 | Donald E. Cutlip Stephan Windecker Roxana Mehran Ashley Boam David J. Cohen Gerrit-Anne van Es P Gabriel Steg Marie-angèle Morel Laura Mauri Pascal Vranckx Eugene McFadden Alexandra Lansky Martial Hamon Mitchell W. Krucoff Patrick W. Serruys | 2007 | Circulation2007，，17： | 4 |
| 4 | Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infraction显示文摘 | Zeller M Steg P Ravisy J | 2005 | Arch Intern Med2005，65，10： | 1 |
| 5 | A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction显示文摘 | Steg P G Grollier G Gallay P | 2001 | Int J Cardiol2001，77，23： | 1 |
| 6 | Low-dose vsstandard-dose un-fractionated heparin for percutaneous coro-nary intervention in acute coronary syndromes treated withfondaparinux:the FUTURA/OASIS-8randomized trial显示文摘 | STEG P G JOLLY S S MEHTA S R | 2010 | JAMA2010，304，12： | 1 |
| 7 | Impact of transtradial and transfemoral coronary interventions on bleeding and net adverse clinical events in acute coronary syndromes显示文摘 | Hamon M Mehta S Steg P G | 2011 | Eurointervention2011，7，1： | 1 |
| 8 | Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL) : a randomised, double-blind, placebo-cantrolled trial显示文摘 | FOX K FORD I STEG P G | 2008 | Lancet2008，372，9641： | 1 |
| 9 | Effect of paraox- onase I polymorphism oll clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction 显示文摘 | Simon T Steg P G Becquemont L | 2011 | Clinical Pharmacology & Therapeutics2011，90，4： | 1 |
| 10 | Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk显示文摘 | John W. Eikelboom Graeme J. Hankey Jim Thom Deepak L. Bhatt P Gabriel Steg Gilles Montalescot S Claiborne Johnston Steven R. Steinhubl Koon-Hou Mak J Donald Easton Christian Hamm Tingfei Hu Keith A.A. Fox Eric J. Topol | 2008 | Circulation2008，，17： | 1 |
| 11 | lvabradine for patients with stable coronary artery disease and left - ventricular systolic dysfunction (BEAUTIFUL) : a randomised, double - blind, placebo - controlled trial显示文摘 | Fox K Ford I Steg P G | 2008 | The Lancet2008，372，9641： | 1 |
| 12 | Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction 显示文摘 | Zeller M Steg P Ravisy J | 2005 | Arch Intern Med2005，65，10： | 1 |
| 13 | The coronary atherosclerosis of the diabetic显示文摘 | Steg P G Karila-Cohen D Feldman L J | 2000 | Arch Mal Coeur Vaiss2000，93，： | 1 |
| 14 | Atherothrombosis and the role ofantiplatelet therapy显示文摘 | Steg P G Dorman S I-I Amarenco P | 2011 | J Thromb Haemost2011，9，1： | 1 |
| 15 | Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial显示文摘 | Shamir R Mehta Jean-Francois Tanguay John W Eikelboom Sanjit S Jolly Campbell D Joyner Christopher B Granger David P Faxon Hans-Jurgen Rupprecht Andrzej Budaj Alvaro Avezum Petr Widimsky Philippe Gabriel Steg Jean-Pierre Bassand Gilles Montalescot Carlos | 2010 | The Lancet2010，，9748： | 1 |
| 16 | Renal impairment and heart failure with preserved ejection fraction early post-myocardial infarction显示文摘AIM:To study if impaired renal function is associated with increased risk of peri-infarct heart failure (HF) in patients with preserved ejection fraction (EF).METHODS:Patients with occluded infarct-related arteries (IRAs) between 1 to 28 d after myocardial infarction (MI) were grouped into chronic kidney disease (CKD) stages based on estimated glomerular filtration rate (eGFR).Rates of early post-MI HF were compared among eGFR groups.Logistic regression was used to explore independent predictors of HF.RESULTS:Reduced eGFR was present in 71.1% of 2160 patients,with significant renal impairment (eGFR < 60 mL/min every 1.73 m2) in 14.8%.The prevalence of HF was higher with worsening renal function:15.5%,17.8% and 29.4% in patients with CKD stages 1,2 and 3 or 4,respectively (P < 0.0001),despite a small absolute difference in mean EF across eGFR groups:48.2 ± 10.0,47.9 ± 11.3 and 46.2 ± 12.1,respectively (P=0.02).The prevalence of HF was again higher with worsening renal function among patients with preserved EF:10.1%,13.6% and 23.6% (P < 0.0001),but this relationship was not significant among patients with depressed EF:27.1%,26.2% and 37.9% (P= 0.071).Moreover,eGFR was an independent correlate of HF in patients with preserved EF (P=0.003) but not in patients with depressed EF (P=0.181).CONCLUSION:A significant proportion of post-MI patients with occluded IRAs have impaired renal function.Impaired renal function was associated with an increased rate of early post-MI HF,the association being strongest in patients with preserved EF.These findings have implications for management of peri-infarct HF. | Vinod Jorapur Gervasio A Lamas Zygmunt P Sadowski Harmony R Reynolds Antonio C Carvalho Christopher E Buller James M Rankin Jean Renkin Philippe Gabriel Steg Harvey D White Carlos Vozzi Eduardo Balcells Michael Ragosta C Edwin Martin Vankeepuram S Srinivas William W Wharton III Staci Abramsky Ana C Mon Shari S Kronsberg Judith S Hochman | 2010 | World Journal of Cardiology2010，2，1： | 1 |
| 17 | Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial显示文摘 | Shamir R Mehta Jean-Francois Tanguay John W Eikelboom Sanjit S Jolly Campbell D Joyner Christopher B Granger David P Faxon Hans-Jurgen Rupprecht Andrzej Budaj Alvaro Avezum Petr Widimsky Philippe Gabriel Steg Jean-Pierre Bassand Gilles Montalescot Carlos | 2010 | The Lancet2010，，9748： | 1 |
| 18 | ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation 显示文摘 | Steg P Gl James S K Atar D | 2012 | Eur Heart J2012，33，20： | 1 |
| 19 | ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation 显示文摘 | STEG P G JAMES S K ATAR D | 2012 | Eur Heart J2012，33，2： | 1 |
| 20 | Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infraction 显示文摘 | Zeller M Steg P Ravisy J | 2005 | Arch Intern Med2005，65，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员